NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 365 filers reported holding NEKTAR THERAPEUTICS in Q1 2018. The put-call ratio across all filers is 0.43 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $898,000 | +5.9% | 25,250 | 0.0% | 0.01% | +16.7% |
| Q1 2019 | $848,000 | +2.2% | 25,250 | 0.0% | 0.01% | -14.3% |
| Q4 2018 | $830,000 | -94.9% | 25,250 | -90.5% | 0.01% | -93.9% |
| Q3 2018 | $16,170,000 | -54.1% | 265,261 | -63.2% | 0.11% | -56.7% |
| Q2 2018 | $35,209,000 | -67.3% | 721,056 | -28.9% | 0.26% | -68.3% |
| Q1 2018 | $107,740,000 | -21.3% | 1,013,932 | -55.8% | 0.83% | -20.7% |
| Q4 2017 | $136,949,000 | +57.1% | 2,293,181 | -36.9% | 1.05% | +56.1% |
| Q3 2017 | $87,178,000 | +18.2% | 3,632,419 | -3.8% | 0.67% | +6.5% |
| Q2 2017 | $73,781,000 | -22.0% | 3,773,983 | -6.4% | 0.63% | -22.5% |
| Q1 2017 | $94,597,000 | +84.1% | 4,030,539 | -3.8% | 0.81% | +80.0% |
| Q4 2016 | $51,396,000 | +12.4% | 4,188,777 | +57.4% | 0.45% | +22.2% |
| Q3 2016 | $45,718,000 | +165.1% | 2,661,104 | +119.6% | 0.37% | +159.9% |
| Q2 2016 | $17,247,000 | – | 1,212,050 | – | 0.14% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HARVEY CAPITAL MANAGEMENT INC | 598,400 | $10,083,000 | 3.98% |
| Opus Point Partners Management, LLC | 348,583 | $5,874,000 | 3.88% |
| Camber Capital Management LP | 3,500,000 | $58,975,000 | 3.81% |
| 1492 Capital Management LLC | 180,601 | $3,043,000 | 2.21% |
| Virtus ETF Advisers LLC | 38,260 | $645,000 | 1.77% |
| Cormorant Asset Management, LP | 765,156 | $12,893,000 | 1.54% |
| Rhenman & Partners Asset Management AB | 581,000 | $9,790,000 | 1.48% |
| Granahan Investment Management | 2,082,155 | $35,084,000 | 1.21% |
| BRIDGER MANAGEMENT, LLC | 1,563,862 | $26,351,000 | 0.87% |
| RICE HALL JAMES & ASSOCIATES, LLC | 899,531 | $15,157,000 | 0.87% |